Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation

Aging Cell

Volumn 12, Issue 3, 2013, Pages 489-498

  Moiseeva, Olga ^a   Deschênes Simard, Xavier ^a   St Germain, Emmanuelle ^a   Igelmann, Sebastian ^a   Huot, Geneviève ^a   Cadar, Alexandra E ^a   Bourdeau, Véronique ^a   Pollak, Michael N ^b   Ferbeyre, Gerardo ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cellular senescence; Cytokines; Metformin; NF B; Senescence

Indexed keywords

I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METFORMIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL AGING; CONTROLLED STUDY; DRUG EFFECT; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; ENZYME ACTIVATION; FIBROBLASTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; I-KAPPA B KINASE; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; METFORMIN; MICE; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

ANIMALIA;

EID: 84877822086     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12075     Document Type: Article

References (45)

1. Adler A. S., Sinha S., Kawahara T. L., Zhang J. Y., Segal E., Chang H. Y. (2007) Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev. 21, 3244-3257.
2. Algire C., Moiseeva O., Deschenes-Simard X., Amrein L., Petruccelli L., Birman E., Viollet B., Ferbeyre G., Pollak M. N. (2012) Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev. Res. (Phila) 5, 536-543.
3. Anisimov V. N., Berstein L. M., Popovich I. G., Zabezhinski M. A., Egormin P. A., Piskunova T. S., Semenchenko A. V., Tyndyk M. L., Yurova M. N., Kovalenko I. G., Poroshina T. E. (2011) If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 3, 148-157.
4. Baker D. J., Wijshake T., Tchkonia T., LeBrasseur N. K., Childs B. G., van de Sluis B., Kirkland J. L., van Deursen J. M. (2011) Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232-236.
5. Bhalla K., Hwang B. J., Dewi R. E., Twaddel W., Goloubeva O. G., Wong K. K., Saxena N. K., Biswal S., Girnun G. D. (2012) Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev. Res. (Phila) 5, 544-552.
6. Bonafe M., Storci G., Franceschi C. (2012) Inflamm-aging of the stem cell niche: breast cancer as a paradigmatic example: breakdown of the multi-shell cytokine network fuels cancer in aged people. BioEssays 34, 40-49.
7. Cesari M., Penninx B. W., Newman A. B., Kritchevsky S. B., Nicklas B. J., Sutton-Tyrrell K., Rubin S. M., Ding J., Simonsick E. M., Harris T. B., Pahor M. (2003) Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108, 2317-2322.
8. Chien Y., Scuoppo C., Wang X., Fang X., Balgley B., Bolden J. E., Premsrirut P., Luo W., Chicas A., Lee C. S., Kogan S. C., Lowe S. W. (2011) Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. 25, 2125-2136.
9. Coppe J. P., Desprez P. Y., Krtolica A., Campisi J. (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99-118.
10. Donato A. J., Black A. D., Jablonski K. L., Gano L. B., Seals D. R. (2008) Aging is associated with greater nuclear NF kappa B, reduced I kappa B alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell 7, 805-812.
11. Dong W., Liu Y., Peng J., Chen L., Zou T., Xiao H., Liu Z., Li W., Bu Y., Qi Y. (2006) The IRAK-1-BCL10-MALT1-TRAF6-TAK1 cascade mediates signaling to NF-kappaB from Toll-like receptor 4. J. Biol. Chem. 281, 26029-26040.
12. Ericsson J., Jackson S. M., Kim J. B., Spiegelman B. M., Edwards P. A. (1997) Identification of glycerol-3-phosphate acyltransferase as an adipocyte determination and differentiation factor 1- and sterol regulatory element-binding protein-responsive gene. J. Biol. Chem. 272, 7298-7305.
13. Ferbeyre G., Lowe S. W. (2002) The price of tumour suppression? Nature 415, 26-27.
14. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., Lowe S. W. (2000) PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14, 2015-2027.
15. Fischer S. M., Hawk E. T., Lubet R. A. (2011) Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev. Res. (Phila) 4, 1728-1735.
16. Formentini L., Sanchez-Arago M., Sanchez-Cenizo L., Cuezva J. M. (2012) The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response. Mol. Cell 45, 731-742.
17. Gilbert L. A., Hemann M. T. (2010) DNA damage-mediated induction of a chemoresistant niche. Cell 143, 355-366.
18. Graham G. G., Punt J., Arora M., Day R. O., Doogue M. P., Duong J. K., Furlong T. J., Greenfield J. R., Greenup L. C., Kirkpatrick C. M., Ray J. E., Timmins P., Williams K. M. (2011) Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50, 81-98.
19. Hacker H., Redecke V., Blagoev B., Kratchmarova I., Hsu L. C., Wang G. G., Kamps M. P., Raz E., Wagner H., Hacker G., Mann M., Karin M. (2006) Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439, 204-207.
20. Hoffmann A., Levchenko A., Scott M. L., Baltimore D. (2002) The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 298, 1241-1245.
21. Jing H., Kase J., Dorr J. R., Milanovic M., Lenze D., Grau M., Beuster G., Ji S., Reimann M., Lenz P., Hummel M., Dorken B., Lenz G., Scheidereit C., Schmitt C. A., Lee S. (2011) Opposing roles of NF-kappaB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev. 25, 2137-2146.
22. Kalariya N. M., Shoeb M., Ansari N. H., Srivastava S. K., Ramana K. V. (2012) Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats. Invest. Ophthalmol. Vis. Sci. 53, 3431-3440.
23. Krtolica A., Parrinello S., Lockett S., Desprez P. Y., Campisi J. (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. U.S.A. 98, 12072-12077.
24. Krysiak R., Okopien B. (2012) Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose. Atherosclerosis doi: 10.1016 (in press).
25. Laberge R. M., Zhou L., Sarantos M. R., Rodier F., Freund A., de Keizer P. L., Liu S., Demaria M., Cong Y. S., Kapahi P., Desprez P. Y., Hughes R. E., Campisi J. (2012) Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell 11, 569-578.
26. Malumbres M., Perez De Castro I., Hernandez M. I., Jimenez M., Corral T., Pellicer A. (2000) Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol. Cell. Biol. 20, 2915-2925.
27. Medina I., Carbonell J., Pulido L., Madeira S. C., Goetz S., Conesa A., Tarraga J., Pascual-Montano A., Nogales-Cadenas R., Santoyo J., Garcia F., Marba M., Montaner D., Dopazo J. (2010) Babelomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling. Nucleic Acids Res. 38, W210-W213.
28. Memmott R. M., Mercado J. R., Maier C. R., Kawabata S., Fox S. D., Dennis P. A. (2010) Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. (Phila) 3, 1066-1076.
29. Mercurio F., Zhu H., Murray B. W., Shevchenko A., Bennett B. L., Li J., Young D. B., Barbosa M., Mann M., Manning A., Rao A. (1997) IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278, 860-866.
30. Meylan E., Burns K., Hofmann K., Blancheteau V., Martinon F., Kelliher M., Tschopp J. (2004) RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat. Immunol. 5, 503-507.
31. Moiseeva O., Bourdeau V., Roux A., Deschenes-Simard X., Ferbeyre G. (2009) Mitochondrial dysfunction contributes to oncogene-induced senescence. Mol. Cell. Biol. 29, 4495-4507.
32. Ohanna M., Giuliano S., Bonet C., Imbert V., Hofman V., Zangari J., Bille K., Robert C., Bressac-de Paillerets B., Hofman P., Rocchi S., Peyron J. F., Lacour J. P., Ballotti R., Bertolotto C. (2011) Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev. 25, 1245-1261.
33. Onken B., Driscoll M. (2010) Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS ONE 5, e8758.
34. Pietras K., Sjoblom T., Rubin K., Heldin C. H., Ostman A. (2003) PDGF receptors as cancer drug targets. Cancer Cell 3, 439-443.
35. Pollak M. (2010) Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev. Res. (Phila) 3, 1060-1065.
36. Pollak M. N. (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2, 778-790.
37. Raimondi C., Falasca M. (2011) Targeting PDK1 in cancer. Curr. Med. Chem. 18, 2763-2769.
38. Rodier F., Coppe J. P., Patil C. K., Hoeijmakers W. A., Munoz D. P., Raza S. R., Freund A., Campeau E., Davalos A. R., Campisi J. (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 11, 973-979.
39. Rongvaux A., Andris F., Van Gool F., Leo O. (2003) Reconstructing eukaryotic NAD metabolism. BioEssays 25, 683-690.
40. Serrano M., Lin A. W., McCurrach M. E., Beach D., Lowe S. W. (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
41. Sun Y., Campisi J., Higano C., Beer T. M., Porter P., Coleman I., True L., Nelson P. S. (2012) Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18, 1359-1368.
42. Tilstra J. S., Robinson A. R., Wang J., Gregg S. Q., Clauson C. L., Reay D. P., Nasto L. A., St Croix C. M., Usas A., Vo N., Huard J., Clemens P. R., Stolz D. B., Guttridge D. C., Watkins S. C., Garinis G. A., Wang Y., Niedernhofer L. J., Robbins P. D. (2012) NF-kappaB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest 122, 2601-2612.
43. Vernier M., Bourdeau V., Gaumont-Leclerc M. F., Moiseeva O., Begin V., Saad F., Mes-Masson A. M., Ferbeyre G. (2011) Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev. 25, 41-50.
44. Wang C., Deng L., Hong M., Akkaraju G. R., Inoue J., Chen Z. J. (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346-351.
45. Zhao T., Yang L., Sun Q., Arguello M., Ballard D. W., Hiscott J., Lin R. (2007) The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat. Immunol. 8, 592-600.